The Prodrug DHED Delivers 17β-Estradiol into the Retina for Protection of Retinal Ganglion Cells and Preservation of Visual Function in an Animal Model of Glaucoma
Cells · 2024
DOI: 10.3390/cells13131126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Ammar Kapic und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA. Hauptthemen laut MEDLINE: Retinal Ganglion Cells, Glaucoma, Prodrugs, Estradiol. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NIA NIH HHS, National Eye Institute and the Office of Research on Women's Health/NIH.
Abstract (Originalsprache)
We report a three-pronged phenotypic evaluation of the bioprecursor prodrug 10β,17β-dihydroxyestra-1,4-dien-3-one (DHED) that selectively produces 17β-estradiol (E2) in the retina after topical administration and halts glaucomatous neurodegeneration in a male rat model of the disease. Ocular hypertension (OHT) was induced by hyperosmotic saline injection into an episcleral vein of the eye. Animals received daily DHED eye drops for 12 weeks. Deterioration of visual acuity and contrast sensitivity by OHT in these animals were markedly prevented by the DHED-derived E2 with concomitant preservation of retinal ganglion cells and their axons. In addition, we utilized targeted retina proteomics and a previously established panel of proteins as preclinical biomarkers in the context of OHT-induced neurodegeneration as a characteristic process of the disease. The prodrug treatment provided retina-targeted remediation against the glaucomatous dysregulations of these surrogate endpoints without increasing circulating E2 levels. Collectively, the demonstrated significant neuroprotective effect by the DHED-derived E2 in the selected animal model of glaucoma supports the translational potential of our presented ocular neuroprotective approach owing to its inherent therapeutic safety and efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
ORCID-Profile: Ammar Kapic, Khadiza Zaman, George C Neagu, Nathalie Sumien, Laszlo Prokai, Katalin Prokai-Tatrai
Förderung
- NEI NIH HHS
- NIA NIH HHS
- National Eye Institute and the Office of Research on Women's Health/NIH
- Robert A. Welch Foundation
- National Eye Institute
- Neurobiology of Aging and Alzheimer’s Disease Training Grant
Zitieren
APA
Kapic, A., Zaman, K., Nguyen, V., Neagu, G. C., Sumien, N., Prokai, L., & Prokai-Tatrai, K. (2024). The Prodrug DHED Delivers 17β-Estradiol into the Retina for Protection of Retinal Ganglion Cells and Preservation of Visual Function in an Animal Model of Glaucoma. Cells. https://doi.org/10.3390/cells13131126
Vancouver
Kapic A, Zaman K, Nguyen V, Neagu GC, Sumien N, Prokai L, et al. The Prodrug DHED Delivers 17β-Estradiol into the Retina for Protection of Retinal Ganglion Cells and Preservation of Visual Function in an Animal Model of Glaucoma. Cells. 2024. doi:10.3390/cells13131126
BibTeX
@article{Kapic2024,
author = {Kapic, Ammar and Zaman, Khadiza and Nguyen, Vien and Neagu, George C and Sumien, Nathalie and Prokai, Laszlo and Prokai-Tatrai, Katalin},
title = {The Prodrug DHED Delivers 17β-Estradiol into the Retina for Protection of Retinal Ganglion Cells and Preservation of Visual Function in an Animal Model of Glaucoma},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13131126}
}
EUVIMED